D5Pharma

Introducing MetVax.

D5Pharma’s brand new cancer vaccine blocks metastasis.

D5Pharma attends BIO 2022.

Our team will be actively seeking partners for our technologies at BIO 2022 in San Diego, 13-16 June.

Targeting CD200R1 with PEG:CCS13.

A unique DNA aptamer that agonises an established immune checkpoint.

Our vision is to deliver a new brand of targeted medicines that will revolutionize healthcare

A new approach to fighting cancer and inflammatory disease

Demand

Design

Discovery

Development

Delivery

D5Pharma’s next-generation screening technique allows us to identify DNA aptamers that have functional characteristics specific to critical therapeutic targets

Read more about our unique approach in these academic publications

Contact investor relations